Cas:306936-95-8 ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate manufacturer & supplier

Chemical Name:ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate

CAS.NO:306936-95-8

Synonyms:ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate

Molecular Formula:C₁₈H₂₄N₂O₂

Molecular Weight:300.39500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:432.8ºC at 760mmHg

Density:1.05g/cm3

Index of Refraction:1.537

PSA:44.12000

Exact Mass:300.18400

LogP:3.71400

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate Use and application,ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate technical grade,usp/ep/jp grade.

Related News: The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate manufacturer Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate supplier In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. ethyl 5-tert-butyl-2-[(3-methylphenyl)methyl]pyrazole-3-carboxylate factory Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.